Cambridge, Cambridgeshire, United Kingdom University of Cambridge Enterprise appeared to be the Corporate Investor, which was created in 2006. The company was established in Europe in United Kingdom. The leading representative office of defined Corporate Investor is situated in the Cambridge.
Besides them, we counted 4 critical employees of this fund in our database.
Among the most popular fund investment industries, there are Health Care, Medical. Among the most popular portfolio startups of the fund, we may highlight Cambridge Epigenetix, Carrick Therapeutics, Colorifix. For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.
The real fund results show that this Corporate Investor is 22 percentage points more often commits exit comparing to other companies. The important activity for fund was in 2016. Despite it in 2019 the fund had an activity. Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. The increased amount of exits for fund were in 2018. This University of Cambridge Enterprise works on 21 percentage points less the average amount of lead investments comparing to the other organizations.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the University of Cambridge Enterprise, startups are often financed by Amadeus Capital Partners, SBRI Healthcare, Roche Venture Fund. The meaningful sponsors for the fund in investment in the same round are Amadeus Capital Partners, Cambridge Angels group, Martlet. In the next rounds fund is usually obtained by Cambridge Innovation Capital, Cambridge Angels group, Amadeus Capital Partners.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Agri-Business Capital Fund (ABC Fund) | - |
| BigPi | Athens, Attiki, Greece |
| Breeze Ventures | Edison, New Jersey, United States |
| Chengfeng Juhui Touzi | China, Guangxi, Nanning |
| Chengzhu Investment Management | China, Shanghai |
| Climate Adaptive Infrastructure | - |
| Curitiba Angels | - |
| IFU | - |
| InComm | Atlanta, Georgia, United States |
| Innovation Engine | Chiyoda, Japan |
| Midas Ventures | Brazil, São Paulo, Sao Paulo |
| SMEDAN | - |
| Strategic Round Capital | Central, Central Region, Singapore |
| The Poarch Band of Creek Indians | Alabama, Atmore, United States |
| U.S. Trust | Florham Park, New Jersey, United States |
| ULTIMA | Chengdu, China, Sichuan |
| Vivium Life Private Equity | - |
| Voice Punch | California, Santa Monica, United States |
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Zetta Genomics | $2M | 08 Feb 2024 | Cambridge, Cambridgeshire, United Kingdom | ||
Xampla | $7M | 30 Jan 2024 | Cambridge, England, United Kingdom | ||
T-Therapeutics | $65M | 15 Nov 2023 | Cambridge, Cambridgeshire, United Kingdom | ||
RoboK | $2M | 29 Jun 2023 | Cambridge, England, United Kingdom | ||
PharmEnable | $8M | 22 May 2023 | Cambridge, England, United Kingdom | ||
ConcR | $1M | 05 May 2023 | London, England, United Kingdom | ||
Zetta Genomics | $2M | 17 Apr 2023 | Cambridge, Cambridgeshire, United Kingdom | ||
Impossible Materials | $3M | 05 Apr 2023 | - | ||
Kalium Health | $1M | 09 Nov 2022 | Cambridge, Cambridgeshire, United Kingdom |
– Nyobolt Raises $10m in Series A Funding
– The round was led by IQ Capital with participation from Cambridge Enterprise and Silicon Valley investors.
– The company intends to use the funds to expand globally, building new facilities, and growing the engineering and operational teams.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Zetta Genomics | $2M | 08 Feb 2024 | Cambridge, Cambridgeshire, United Kingdom | ||
Xampla | $7M | 30 Jan 2024 | Cambridge, England, United Kingdom | ||
T-Therapeutics | $65M | 15 Nov 2023 | Cambridge, Cambridgeshire, United Kingdom | ||
RoboK | $2M | 29 Jun 2023 | Cambridge, England, United Kingdom | ||
PharmEnable | $8M | 22 May 2023 | Cambridge, England, United Kingdom | ||
ConcR | $1M | 05 May 2023 | London, England, United Kingdom | ||
Zetta Genomics | $2M | 17 Apr 2023 | Cambridge, Cambridgeshire, United Kingdom | ||
Impossible Materials | $3M | 05 Apr 2023 | - | ||
Kalium Health | $1M | 09 Nov 2022 | Cambridge, Cambridgeshire, United Kingdom |
